Innovent

Established in 2011, Innovent Biologics (“Innovent”) (1801.HK) is committed to developing, manufacturing, and commercializing high-quality innovative medicines for the treatment of major diseases that are affordable to ordinary people. The founder, Dr. De-Chao Michael Yu, has engaged in the biopharmaceutical innovation research for over 20 years, invented three Class I new drugs, and promoted their development and commercialization. Innovent has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases, and other major therapeutic areas, with 18 in clinical development, 5 in Phase 3 or pivotal clinical trials, and 2 under NDA reviews by the NMPA with priority review status. The TYVYT® (Sintilimab Injection), co-developed with Eli Lily, has been the only PD-1 inhibitor included in the NRDL since 2019. After its public listing in HKEX, Innovent has become the second Chapter 18A company that satisfies and even well exceeds the revenue and market capitalization tests for the dis-application. Overall, Innovent has distinguished itself among tremendous bio-pharmaceutical companies with continuing innovative achievements.